Reviewer’s report

Title: Case report Pregabalin induced visual hallucinations – A rare adverse reaction

Version: 1 Date: 16 Dec 2019

Reviewer: Gaetano Zaccara

Reviewer's report:

Pregabalin induced visual hallucinations - A rare adverse reaction

This is a report on a rare adverse event induced by pregabalin

I think that this manuscript is interesting. However, there are some points that would be nice to clarify

Introduction Pregabalin is an isomer (analogue) of gamma-aminobutyric acid (GABA). I would say with more precision "Pregabalin is a 3-isobutyl derivative of gamma-amino butyric acid (GABA)"

What means exactly: in "over-excited" presynaptic neurons? This phrase is not clear Is it true also in patients with anxiety?

Discussion

Page 6, line 16th Psychotic symptoms…..Only vigabatrin and topiramete are cited. I would add also other AEDs.. At least also zonisamide may cause psychosis. In addition, I would add or change the reference (Besag et al., is not updated!)

At the end of discussion, regarding the hypothesized pathophysiological mechanisms causing visual hallucinations it is affirmed "In predisposed individuals, an increase of pregabalin plasma levels might result in relative over-attenuation of inhibitory systems, and thus result in abnormal over-synchronization" It is not clear to me what exactly means this phrase. In particular "over-attenuation of inhibitory systems" and how this mechanism may cause hallucinations

Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.

Yes

Does the work include the necessary controls?
If not, please specify which controls are required in your comments to the authors.

Unable to assess

Are the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.

Yes
Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?
If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.

Not relevant to this manuscript

Quality of written English
Please indicate the quality of language in the manuscript:

Acceptable

Declaration of competing interests
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

No, I declare that I have no competing interests

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal